Sentences with phrase «life sciences venture capital»

TCG's investment strategy runs counter to the prevailing trend in life sciences venture capital toward assembling diversified portfolios of later stage, single product - orientated companies across multiple industry sectors, with proximity to value inflection points and the early identification of a Pharma «buyer» as key investment considerations.

From 2010 until joining Mereo, Dr. Scots - Knight was the Managing Partner of Phase4 Partners Ltd., or Phase4, a global life science venture capital firm.

TPG Biotech is TPG's life science venture capital platform.

Not exact matches

• Altitude Life Science Ventures, a Seattle - based venture capital firm, is seeking to raise $ 125 million for its third fund, according to an SEC filing.

About Pappas Capital Founded in 1994, Pappas Capital invests exclusively in the life sciences sector — biotechnology, biopharmaceuticals, drug delivery, medical devices and related ventures — across the United States and Canada.

Boston Scientific Group led the round, and was joined by Hatteras Venture Partners, Synergy Life Science Partners, Lord Baltimore Investment Partners, Mountain Group Capital, and Sovereign's Capital.

Sam Hogg is a venture partner with Open Prairie Ventures, a Midwest - based venture - capital fund investing in agriculture, life - science and information technology.

Both the central government and local governments, for example, help fund Chinese healthcare startups, according to Marietta Wu, managing director of the life sciences venture fund Quan Capital.

• NRD Capital Management LLC made an investment of an undisclosed amount in FundRx, a New York City - based venture capital platform that invests in healthcare and life sciences stCapital Management LLC made an investment of an undisclosed amount in FundRx, a New York City - based venture capital platform that invests in healthcare and life sciences stcapital platform that invests in healthcare and life sciences startups.

Before joining Icon, Taki was the VP of Investor Relations for SB Life Science, a healthcare - focused venture capital firm sponsored by Softbank Corporation.

Rigontec is supported by a consortium of experienced life science investors including Wellington Partners, Boehringer Ingelheim Venture Fund, NRW.BANK, High - Tech Gründerfonds (HTGF), Forbion Capital Partners, Sunstone Capital and MP Healthcare Venture Management.

5AM Ventures is an early - stage venture capital firm focused on building next - generation life science companies.

«We are impressed by Pappas Capital's life science and venture expertise and the specific commitment that the firm has made to the area of rare diseases.»

Art has over 30 years of operating experience as a pharmaceutical and biotechnology industry executive and venture capital investor in life science companies.

Ysios Capital is a leading Spanish venture capital firm that provides private equity financing to early - and mid-stage human healthcare and life science companies with a special focus on pharmaceuticals, diagnostics and medical dCapital is a leading Spanish venture capital firm that provides private equity financing to early - and mid-stage human healthcare and life science companies with a special focus on pharmaceuticals, diagnostics and medical dcapital firm that provides private equity financing to early - and mid-stage human healthcare and life science companies with a special focus on pharmaceuticals, diagnostics and medical devices.

The National Venture Capital Association has reported that, in 2014, venture capital investment in the life sciences was at its highest level since 2008: in biotechnology, $ 6.0 billion was invested in 470 deals and, in life sciences overall, $ 8.6 billion in 789 deals (including biotechnology and medical deVenture Capital Association has reported that, in 2014, venture capital investment in the life sciences was at its highest level since 2008: in biotechnology, $ 6.0 billion was invested in 470 deals and, in life sciences overall, $ 8.6 billion in 789 deals (including biotechnology and medical deCapital Association has reported that, in 2014, venture capital investment in the life sciences was at its highest level since 2008: in biotechnology, $ 6.0 billion was invested in 470 deals and, in life sciences overall, $ 8.6 billion in 789 deals (including biotechnology and medical deventure capital investment in the life sciences was at its highest level since 2008: in biotechnology, $ 6.0 billion was invested in 470 deals and, in life sciences overall, $ 8.6 billion in 789 deals (including biotechnology and medical decapital investment in the life sciences was at its highest level since 2008: in biotechnology, $ 6.0 billion was invested in 470 deals and, in life sciences overall, $ 8.6 billion in 789 deals (including biotechnology and medical devices).

Represented venture capital fund in its investment and purchase of preferred stock of various life science companies in which it is lead investor.

Our Emerging Growth and Venture Capital practice group assists start - ups and emerging companies in various fields, including information technology, telecommunications, life sciences and clean - tech.

Founded in 1981, Zero Stage Capital is a venture capital firm that invests in emerging growth companies in the following technology sectors: information technology, communications, life sciences, and energy techCapital is a venture capital firm that invests in emerging growth companies in the following technology sectors: information technology, communications, life sciences, and energy techcapital firm that invests in emerging growth companies in the following technology sectors: information technology, communications, life sciences, and energy technology.

The round also included Capital G, which is Alphabet's growth - stage venture arm, and its life sciences business Verily.

These include life science industry representatives from pharmaceutical, medical devices and diagnostic industries, clinical innovators, hospital executives, payers, policy makers, multidisciplinary researchers, patient advocates, angel, venture capital investors and academia.

Art has over 30 years of operating experience as a pharmaceutical and biotechnology industry executive, and venture capital investor in life science companies.

SVB Financial Group engages in the provision of diversified financial services to emerging, growth and established technology companies and the life science, cleantech, venture capital, private equity and premium wine markets.

Peter is a seasoned transactional lawyer with a practice focused on the representation of life science, robotics, technology, venture capital, E-commerce, and other consumer companies.

In the Private Equity: Venture Capital Investment category, «Foley Hoag has historically positioned itself to handle venture transactions within the software and technology industries, but has recently expanded into the advanced energy and life sciences sVenture Capital Investment category, «Foley Hoag has historically positioned itself to handle venture transactions within the software and technology industries, but has recently expanded into the advanced energy and life sciences sventure transactions within the software and technology industries, but has recently expanded into the advanced energy and life sciences sectors.

«These dedicated individuals are representative of our firm's core strengths in life sciences, venture capital and emerging companies, private equity, technology, M&A and healthcare,» said Foley Hoag co-managing partner Jeffrey Collins.

Mr. Smith represents private companies in a broad range of industries and sectors, including venture capital, life sciences, software, internet, real estate, manufacturing, retail, telecommunications and energy (including oil and gas).

«The addition of Robert Chow to our Emerging Companies and Venture Capital practice group will benefit many of our clients, especially those in the technology, healthcare and life sciences areas,» said Foley Hoag Co-Managing Partner Kenneth Leonetti.

It is home to a «well - known IP department» and has a «strong reputation in the venture capital, technology and life sciences fields».

While venture capital is a well - established principle in America and Asia — an estimated 10 % of Singapore's venture capital funds support the life sciences industry — this is less the case in Europe, where many academic startups rely on government grants for initial funding.

A new report ranks the top 10 «clusters» for the sector, based on factors including concentration of life sciences jobs, venture capital funding and National Institute of Health funding, among others.

In addition to life sciences companies, tenants in the Mission Bay center include venture capital firms and academic researchers.